v3.26.1
10-Q Condensed Consolidated Statements of Temporary Equity and Shareholders’ Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common shares
SVS
Common shares
MVS
 [3]
Additional paid-in capital
Treasury
shares
Accumulated other comprehensive loss
Accumulated
deficit
Redeemable non-controlling interest, beginning balance at Dec. 31, 2022 $ 121,113            
Changes in redeemable non-controlling interest contingency              
Foreign currency translation gain (loss) 4,511            
Excess redemption value above carrying value [1] 0            
Net income (loss) (9,140)            
Redeemable non-controlling interest, ending balance at Dec. 31, 2023 120,650            
Common stock, beginning balance (in shares) at Dec. 31, 2022   207,840,042 [2] 31,323,568        
Balance, beginning of period at Dec. 31, 2022 1,279,705     $ 2,163,061 $ (5,208) $ (18,594) $ (859,554)
Changes in stockholders equity              
Foreign currency translation gain (loss) 6,719         6,719  
Exercise of stock options (in shares) [2]   70,590          
Exercise of stock options 48     48      
Issuance of SVS for settlement of RSUs (in shares) [2],[4]   533,768          
Share-based compensation: equity classified awards 20,010     20,010      
Net comprehensive loss attributable to Curaleaf Holdings, Inc. (281,197) [5]           (281,197)
Common stock, ending balance (in shares) at Dec. 31, 2023   213,252,365 [2] 31,323,568        
Balance, end of period at Dec. 31, 2023 1,050,642     2,204,318 (1,050) (11,875) (1,140,751)
Changes in redeemable non-controlling interest contingency              
Foreign currency translation gain (loss) (4,633)            
Excess redemption value above carrying value 22,746            
Net income (loss) (6,584)            
Redeemable non-controlling interest, ending balance at Dec. 31, 2024 132,179            
Changes in stockholders equity              
Foreign currency translation gain (loss) (8,205)         (8,205)  
Exercise of stock options (in shares) [2]   25,130          
Exercise of stock options 156     156      
Issuance of SVS for settlement of RSUs (in shares) [2],[4]   1,076,186          
Issuance of SVS for settlement of PSUs (in shares) [2],[4]   132,179          
Excess redemption value above carrying value (22,746)     (22,746)      
Share-based compensation: equity classified awards 25,696     25,696      
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ (215,423) [5]           (215,423)
Common stock, ending balance (in shares) at Dec. 31, 2024 250,019,639 218,696,071 [2],[6] 31,323,568        
Balance, end of period at Dec. 31, 2024 $ 861,214     2,237,468 0 (20,080) (1,356,174)
Changes in redeemable non-controlling interest contingency              
Foreign currency translation gain (loss) 2,756            
Excess redemption value above carrying value 13,327            
Net income (loss) 817            
Redeemable non-controlling interest, ending balance at Mar. 31, 2025 149,079            
Changes in stockholders equity              
Extinguishment of convertible notes by issuance of SVS (in shares) [6]   1,427,532          
Extinguishment of convertible notes — issuance of SVS [6] 16,500     16,500      
Foreign currency translation gain (loss) 6,063         6,063  
Exercise of stock options (in shares) [6]   33,333          
Exercise of stock options 10     10      
Issuance of SVS for settlement of RSUs (in shares) [6],[7]   556,208          
Issuance of SVS for settlement of PSUs (in shares) [6],[7]   119,983          
Excess redemption value above carrying value (13,327)     (13,327)      
Share-based compensation: equity classified awards 4,624     4,624      
Net comprehensive loss attributable to Curaleaf Holdings, Inc. (61,063)           (61,063)
Common stock, ending balance (in shares) at Mar. 31, 2025   220,833,127 [6] 31,323,568        
Balance, end of period at Mar. 31, 2025 814,021     2,245,275   (14,017) (1,417,237)
Redeemable non-controlling interest, beginning balance at Dec. 31, 2024 132,179            
Changes in redeemable non-controlling interest contingency              
Foreign currency translation gain (loss) 8,655            
Excess redemption value above carrying value 42,294            
Net income (loss) 2,917            
Redeemable non-controlling interest, ending balance at Dec. 31, 2025 $ 83,931            
Common stock, beginning balance (in shares) at Dec. 31, 2024 250,019,639 218,696,071 [2],[6] 31,323,568        
Balance, beginning of period at Dec. 31, 2024 $ 861,214     2,237,468 0 (20,080) (1,356,174)
Changes in stockholders equity              
Extinguishment of convertible notes by issuance of SVS (in shares) [2]   1,427,532          
Extinguishment of convertible notes — issuance of SVS [2] 16,500     16,500      
Foreign currency translation gain (loss) 18,272         18,272  
Exercise of stock options (in shares) [2]   621,424          
Exercise of stock options 256     256      
Issuance of SVS for settlement of RSUs (in shares) [2],[4]   872,741          
Issuance of SVS for settlement of PSUs (in shares) [2],[4]   119,983          
Excess redemption value above carrying value (42,294)     (42,294)      
Share-based compensation: equity classified awards 30,707     30,707      
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ (231,070)           (231,070)
Common stock, ending balance (in shares) at Dec. 31, 2025 257,491,582 226,168,014 [2],[6] 31,323,568        
Balance, end of period at Dec. 31, 2025 $ 756,350     2,345,402 $ 0 (1,808) (1,587,244)
Changes in redeemable non-controlling interest contingency              
Foreign currency translation gain (loss) 3,701            
Excess redemption value above carrying value 381            
Net income (loss) (16)            
Redeemable non-controlling interest, ending balance at Mar. 31, 2026 87,997            
Changes in stockholders equity              
Foreign currency translation gain (loss) $ (8,354)         (8,354)  
Exercise of stock options (in shares) 996,576 996,576 [6]          
Exercise of stock options $ 478     478      
Issuance of SVS for settlement of RSUs (in shares) [6],[7]   1,995,496          
Issuance of SVS for settlement of PSUs (in shares) [6],[7]   928,214          
SVS withheld to satisfy statutory tax withholding obligations (in shares) [6],[8]   (920,404)          
SVS withheld to satisfy statutory tax withholding obligations [6],[8] (6,444)     (6,444)      
Excess redemption value above carrying value (381)     (381)      
Share-based compensation: equity classified awards 9,664     9,664      
Net comprehensive loss attributable to Curaleaf Holdings, Inc. $ 69,799           69,799
Common stock, ending balance (in shares) at Mar. 31, 2026 260,491,464 229,167,896 [6] 31,323,568        
Balance, end of period at Mar. 31, 2026 $ 821,112     $ 2,348,719   $ (10,162) $ (1,517,445)
[1]
(1) Amounts reported in the Company’s Annual Financial Statements for the years ended December 31, 2023 have been recast to reflect reclassification of Missouri and Hemp-derived THC operations as discontinued operations.
[2]
*as defined in Note 1 — Operations of the Company
[3]
***as defined in Note 2 — Basis of presentation
[4]
**as defined in Note 3 — Significant accounting policies
[5]
(1) Amounts reported in the Company’s Annual Financial Statements for the years ended December 31, 2023 have been recast to reflect reclassification of Missouri and Hemp-derived THC operations as discontinued operations.
[6]
*as defined in Note 1 — Operations of the Company
[7]
**as defined in Note 3 — Significant accounting policies
[8]
(1) In connection with the Company’s net share settlement (withhold-to-cover) of PSUs** and RSUs** that vested during three months ended March 31, 2026.